Topic: tyrosine kinase inhibitors
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
The past week ushered in discoveries that could inspire new treatments for Lyme disease and several cancers.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a series C financing.
Astellas has halted a phase 3 trial of ASP8273 in NSCLC and scrapped plans to start other development programs targeting the indication.
A team at the University of Texas has shown a drug combo that might stop chronic myeloid leukemia--while offering the drug at a more reasonable price tag.